Vestibular Migraine Clinical Trial
Official title:
SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines
Verified date | March 2024 |
Source | Otolith Labs |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo. Participants will be: - Enrolled up to 50 days; enrollment, 14 days in Baseline Phase (no device), 7 days in Transition Phase, 28 days in Treatment Phase (study device) - Randomized and stratified into groups based on the referring clinic to be assigned one study device - Asked to use the study device as instructed by the study coordinator - Asked to submit daily diaries reporting their symptoms and use of device, and to participate in tele-health visits with study coordinators - Asked to provide their vertigo diagnosis from their physician - Compensated for their participation Researchers will compare the randomized groups to determine which group responds better to which device.
Status | Enrolling by invitation |
Enrollment | 200 |
Est. completion date | September 30, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: To be eligible to participate in this study, an individual must meet all the following criteria: - Diagnosed as having Vestibular Migraine (VM) (aka Migraine Associated Vertigo) The participant's diagnosis must be provided by a physician, Board certified in Otolaryngology or Neurology, from one of the study's approved clinics. Diagnosis for VM must follow Bárány Society's "International Classification of Vestibular Disorders", which contains the Society's consensus diagnostic criteria for VM [Lempert 2022, sect. 3]. - Male or female subjects, age 18 to 75 years old inclusive on day of enrollment - Residing in the United States - Vestibular migraines that have been recurrent for at least 90 days - Score from 36 to 90 inclusive on the Dizziness Handicap Inventory (DHI) (corresponding to moderate to severe vertigo) - A smartphone, computer or tablet and access to internet to complete study procedures and study meetings - Willing and able to comply with study procedures - Willingness to use Venmo or Paypal for study stipend Exclusion Criteria: - Females who are pregnant or trying to become pregnant - Enrolled in previous Otolith Lab-sponsored clinical trial - Currently taking part in another interventional trial - Surgery to the skull base within the last 6 months or plans for surgery to the skull during enrollment period - Skull or neck implants - History of vitreous detachment in the last 90 days - Superior canal dehiscence or otic capsule dehiscence - Diagnosed hyperacusis - Undergoing vestibular rehabilitation therapy or planning to start vestibular rehabilitation therapy during the study - History of cerebrovascular disorders - Posterior fossa tumors, vestibular schwannoma - Cerebellar degeneration (progressive worsening of neurons behind the brain stem) - Taking benzodiazepines (e.g., clonazepam, lorazepam, diazepam) - Initiation of calcitonin gene-related peptide inhibitor treatment within 4 weeks prior to beginning of trial - Cognitive impairment or inability to follow study procedures |
Country | Name | City | State |
---|---|---|---|
United States | Otolith Labs | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Otolith Labs | MCRA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DHI Change in Scores | Reduction in final "Dizziness Handicap Inventory" (DHI) score by at least 12 points, compared to transition DHI score | Day 23 - Day 51 | |
Secondary | Number of related adverse events | Assessment of any related adverse events and device usage | Day 23 - Day 51 | |
Secondary | Change in number of vestibular migraine episodes weekly | Assessment of the number of vestibular migraine episodes each week | Day 1 - Day 51 | |
Secondary | Global Impression of Change (severity of episodes) | Assessment of the results of Global Impression of Change questionnaire and impacts on the severity of episodes | Day 51 | |
Secondary | DHI change from transition to end of study | Assessment of overall changes in DHI score from transition time point to the end of the study | Day 23 - Day 51 | |
Secondary | Device responder rate | Assessment of the responder rate of the study arms and their device usage | Day 23 - Day 51 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Recruiting |
NCT04417361 -
Galcanezumab for Vestibular Migraine
|
Phase 2 | |
Enrolling by invitation |
NCT05396482 -
Assesment of Hearing in Patients With Vestibular Migra
|
||
Completed |
NCT03979677 -
Effects of Lifestyle Modification on Vestibular Migraine
|
N/A | |
Completed |
NCT05157399 -
Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness
|
N/A | |
Not yet recruiting |
NCT05914207 -
Non-Pharmacological Treatment of Vestibular Migraine in Children and Adolescent
|
N/A | |
Enrolling by invitation |
NCT06417684 -
Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine
|
Early Phase 1 | |
Recruiting |
NCT04939922 -
China Headache Registry Study
|
||
Recruiting |
NCT05472675 -
Local Sensory Nerve Block in the Treatment of Vestibular Migraine
|
N/A | |
Recruiting |
NCT05418218 -
International Headache Registry Study
|
||
Suspended |
NCT04026516 -
CAVA: Dizziness Trial
|
N/A | |
Withdrawn |
NCT03578354 -
4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
|
Phase 2 | |
Completed |
NCT02350985 -
Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine
|
Phase 4 | |
Completed |
NCT03417596 -
Vestibular Rehabilitation in Patients With Vestibular Migraine
|
N/A | |
Not yet recruiting |
NCT04664088 -
Acupuncture for Prophylaxis of Vestibular Migraine
|
N/A | |
Completed |
NCT05960786 -
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
|
N/A | |
Completed |
NCT02447991 -
Rizatriptan for Episodic Dizziness in Vestibular Migraine
|
Phase 2/Phase 3 | |
Recruiting |
NCT04935970 -
Metabolic Disorders and Vertigo
|
||
Not yet recruiting |
NCT05508139 -
The Role Of Vestibular Rehabilitation Therapy In Management Of Vestibular Migraine Patients
|
||
Completed |
NCT01669304 -
Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness
|
Phase 1 |